Adam Feuerstein

It’s been a long road for MannKind Corporation (NASDAQ: MNKD) and its Afrezza inhalable insulin product. However, a generous new FDA label this week may be the light at the end of the tunnel. Here’s a look at inhalable insulin’s long journey and what the new FDA ruling means for...

Buy the rumor, sell the news is an adage many traders vouch by. With the market operating on a forward-looking basis, any imminent event or rumor could send traders piling into the stock only to liquidate when the news is released or the rumor is confirmed. By doing so, they make a neat profit....

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock initially jumped above $41 per share on Thursday after the FDA granted Breakthrough Designation to the company’s dementia-related psychosis drug candidate Pimavanserin. However, the stock quickly reversed direction as the market digested the...

Shares of Zogenix, Inc. (NASDAQ: ZGNX) traded higher by 200 percent early Friday morning after the company announced top-line results from a phase 3 clinical trial exploring its drug called ZX008 for the treatment of Dravet syndrome. Zogenix said that its trial met its primary objective of...

Investors and analysts don’t seem to be in lockstep when it comes to NewLink Genetics Corp (NASDAQ: NLNK)’s potential. On Monday, the biotech firm secured Buy reiterations from Stifel Nicolaus and Cantor Fitzgerald, and last week, it earned upgrades to Buy from Jefferies and Baird...

The initial reaction from Wall Street analysts following Gilead Sciences, Inc. (NASDAQ: GILD)’s nearly $12 billion buyout of Kite Pharma Inc (NASDAQ: KITE) was mostly bullish, although price targets and ratings on Gilead are a mixed bag on Wall Street. However, this week’s trading...

Shares of Puma Biotechnology Inc (NASDAQ: PBYI) soared higher by more than 70 percent on Monday after the U.S. Food and Drug Administration posted briefing documents ahead of the regulatory body's review of Puma's PB272 (neratinib) for the extended adjuvant treatment of HER2-positive early stage...

TherapeuticsMD Inc (NYSE: TXMD) shares were down 44.4 percent in 2016. By virtue of an advance seen since late February to early April, the stock trimmed some of the losses only to plunge headlong on the news it has received a letter from the FDA related to its pending application of Yuvvexy...

Since 1980, tens of thousands of cyclists have ridden in the Pan-Mass Challenge to raise a total of $547 million for the Jimmy Fund of the Dana-Farber Cancer Institute. The race proceeds are the Institute's greatest contribution and comprise more than 50 percent of the Jimmy Fund’s annual...

On Wednesday, TheStreet biotech reporter Adam Feuerstein raised alarm that an unknown source paid to convert Seeking Alpha posts about Neurotrope Inc (NASDAQ: NTRP) into unofficial promotional pieces for bryostatin, the company's lead drug candidate. Neurotrope denied any involvement. "The...

Did you miss today's PreMarket Prep? Here are some of the highlights from the show. 'The Study Failed' TheStreet's Adam Feuerstein joined this morning to analyze Neurotrope Inc (NASDAQ: NTRP)'s data results. According to the company, the Phase 2 data for their Alzheimer's...

Neurotrope Inc (NASDAQ: NTRP) announced “positive topline results” for its leading Alzheimer's drug in a press release, but investors weren’t fooled. “The study failed,” Adam Feuerstein, biotech reporter at TheStreet, said Monday on Benzinga’s PreMarket Prep...

After hearing Neurotrope Inc (NASDAQ: NTRP) would announce results of its Phase 2 study of potential Alzheimer’s Disease (AD) treatment Bryostatin-1, biotech investors have waited with baited breath through the weekend. On Monday, Neurotrope reported positive top-line results from its Phase 2...

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are up more than 6.5 percent Friday after the company reported first-quarter net revenue from EXONDYS 51 of $16.3 million and guided for $95 million in revenue for the full year, up from previous guidance of $80 million. In addition to the revenue beat...

TherapeuticsMD Inc (NYSE: TXMD) has waned as much as 40 percent since April 7, when the company received an FDA letter noting deficiencies in the new drug application for vulvovaginal atrophy treatment, Yuvvexy (TX-004HR). The regulatory agency said the deficiencies preclude talk of the drugs...